Rituximab for secondary progressive multiple sclerosis: a case series.

Area of Science:

• Neuroimmunology
• Clinical Neurology

Background:

• Limited treatment options exist for secondary progressive multiple sclerosis (SPMS).
• Rituximab, a monoclonal antibody, targets B cells and has shown efficacy in relapsing-remitting MS.

Observation:

• This observational study evaluated three SPMS patients treated with rituximab for at least 15 months.
• Clinical data and cerebrospinal fluid (CSF) analyses were collected.

Findings:

• No severe adverse events were reported.
• The Expanded Disability Status Scale (EDSS) scores stabilized in all patients, halting previous progression.
• B cell reconstitution following rituximab treatment was variable.
• Serial CSF examinations indicated a decrease in intrathecal IgG synthesis.

Implications:

• Rituximab demonstrates potential efficacy in managing active SPMS.
• The variable immune reconstitution necessitates further research into optimal rituximab dosing and treatment intervals.
• This study highlights the need for personalized therapeutic strategies in progressive MS.